Peptidylarginine deiminases 4 as a promising target in drug discovery

Chao Yang, Zhen Zhen Dong, Jing Zhang, Dehong Teng, Xinzhi Luo, Dan Li*, Yingtang Zhou*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

26 Citations (Scopus)

Abstract

Peptidylarginine deaminase 4 (PAD4) is a crucial post-translational modifying enzyme catalyzing the conversion of arginine into citrulline residues, and mediating the formation of neutrophil extracellular traps (NETs). PAD4 plays a vital role in the occurrence and development of cardiovascular diseases, autoimmune diseases, and various tumors. Therefore, PAD4 is considered as a promising drug target for disease diagnosis and treatment. More and more efforts are devoted to developing highly efficient and selective PAD4 inhibitors via high-throughput screening, structure-based drug design and structure-activity relationship study. This article outlined the physiological and pathological functions of PAD4, and corresponding representative small molecule inhibitors reported in recent years.

Original languageEnglish
Article number113840
Number of pages11
JournalEuropean Journal of Medicinal Chemistry
Volume226
Early online date9 Sept 2021
DOIs
Publication statusPublished - 15 Dec 2021

User-Defined Keywords

  • Autoimmune disease
  • Citrullination
  • Histone
  • NETs
  • PAD4 inhibitor

Fingerprint

Dive into the research topics of 'Peptidylarginine deiminases 4 as a promising target in drug discovery'. Together they form a unique fingerprint.

Cite this